AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (1.3 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Publishing Language: Chinese | Open Access

Design strategies of five candidate drugs for neurological diseases based on functional protein-targeted peptide and small molecule compound development

Yiran TANG, Ying LI, Tingyou LI ( )
School of Pharmacy, Nanjing Medical University, Nanjing 211166, China
Show Author Information

Abstract

Peptide compounds exhibit the advantages of high target affinity, strong specificity, and low immunogenicity. Therefore, after clarifying the therapeutic target, peptide compounds can be obtained as lead compounds via the protein fragment truncation strategy. However, the inherent structural limitations of peptide compounds result in several drawbacks, such as poor stability, low oral bioavailability, and high production costs. In contrast, small-molecule compounds possess the prominent advantages of high oral bioavailability, metabolic stability, and low production costs. Thus, it is particularly important to screen small-molecule compounds that can mimic the action mode of peptides and retain biological activity by analyzing the interaction modes between peptide compounds and target proteins. Focusing on intractable brain diseases such as Alzheimer's disease, this paper systematically elaborates on the research and development pathway of deriving active peptide compounds from functional proteins, deciphering the interaction modes between peptides and target proteins, and further obtaining targeted small-molecule compounds through five typical transformation cases, which can provide a valuable reference for subsequent compound design.

CLC number: R918 Document code: A Article ID: 1007-4368(2026)06-927-08

References

【1】
【1】
 
 
Journal of Nanjing Medical University (Natural Sciences)
Pages 927-934

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
TANG Y, LI Y, LI T. Design strategies of five candidate drugs for neurological diseases based on functional protein-targeted peptide and small molecule compound development. Journal of Nanjing Medical University (Natural Sciences), 2026, 46(6): 927-934. https://doi.org/10.7655/NYDXBNSN260146

2

Views

0

Downloads

0

Crossref

Received: 27 January 2026
Revised: 09 April 2026
Accepted: 11 April 2026
Published: 15 June 2026
© 2026 Editorial Board of Journal of Nanjing Medical University(Natural Sciences)

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).